Intuitive Surgical's AI Upgrade Transforms Robotic Lung Surgery

Intuitive Surgical, the maker of the da Vinci robotic system, is expanding its influence in AI-driven surgery. The company recently secured FDA approval for an AI upgrade to its Ion endoluminal system. This move comes as demand for robotic-assisted procedures continues to grow worldwide.

The latest enhancements aim to improve real-time decision-making during lung surgeries, marking another step toward smarter, data-backed operations.

The FDA's 2025 approval allows Intuitive Surgical's Ion system to use AI for instant analysis during lung procedures. This upgrade helps surgeons adjust to patient movements more precisely. The technology builds on the company's vast database of surgical data, which tracks tool movements, outcomes, and complications.

Demand for robotic surgery is rising fast. Over 11,106 da Vinci systems are now installed globally—a 12% jump from 2024. The number of surgeries performed with these robots climbed 18% in the same period. Hospitals and clinics increasingly rely on these systems for minimally invasive operations.

Intuitive Surgical's data holds significant value beyond its own products. The company could licence its insights, develop new AI tools, or even become an acquisition target. Analysts note the stock's high price-to-earnings ratio of 66, reflecting investor confidence in its AI-driven growth.

Looking ahead, the potential for fully autonomous AI surgery—tailored to individual patients—remains a long-term goal. For now, the focus stays on refining robotic assistance and data-driven improvements in precision.

The FDA's latest approval strengthens Intuitive Surgical's position in AI-enhanced surgery. With more da Vinci systems in use and rising procedure numbers, the company's data advantage continues to grow. Future developments may further transform how surgeries are planned, executed, and optimized.